Drug Trial Radar · NCT06048133
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
33
Planned (sponsor's estimate)
Start
Mar 8, 2024
Primary completion
Dec 2026
Study completion Jul 2027
Sponsor
- Lead sponsor
- Nataliya UbohaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Arcus Biosciences, Inc.; Gilead Sciences; University of Wisconsin, Madison
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2 study of gemcitabine, cisplatin, zimberelimab (AB122) and quemliclustat (AB680) in subjects with untreated advanced biliary tract cancers (BTC). The study will include a safety run-in involving 6 study participants. The goal of the safety run-in is to screen for early safety signals of the proposed drug combination. Trial enrollment can continue while full safety assessment is being completed for the first 6 subjects. Participants will receive 4 cycles of combination therapy as described. After 4 cycles (\~6 months), cisplatin will be discontinued, while gemcitabine, zimberelimab (AB122), and quemliclustat (AB680) will be continued. Subjects will be treated until disease progression or development of intolerable toxicities. In total, there will be up to 39 participants on the study.
Conditions
- Biliary Tract Carcinoma
- Cholangiocarcinoma
- Bile Duct Cancer
Interventions
GemcitabineDrug
Gemcitabine IV: Day 1, 8, 22, and 29 every 42 days
CisplatinDrug
Cisplatin IV: Day 1, 8, 22, and 29 every 42 days of Cycles 1-4 only.
ZimberelimabDrug
Zimberelimab IV: Day 1 and 22 every 42 days
QuemliclustatDrug
Quemliclustat IV: Day 1, 15, 29 every 42 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimate the progression free survival (PFS) with gemcitabine, cisplatin, quemliclustat (AB680) and zimberelimab (AB122) in patients with advanced BTCs.Time frame: 2 years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana
University of Michigan Health System
Ann Arbor, Michigan
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
University of Wisconsin
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.